C Rad (CRAD B.ST) Stock Price

C Rad Price

OMX·CLOSED
34.90SEK-0.10 (-0.29 %)
Market closed

Over the last 10 years C Rad grew revenue by 20.9% annually, reaching 441.90 M SEK. Earnings per share have declined at 10.6% per year over the last 7 years. For C Rad, the net margin of 2.4% is down versus 9.6% a few years ago. The consensus 12-month price target for C Rad is 44.88 SEK, about 28.6% above where the stock trades today. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.

C Rad stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of C Rad over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how C Rad stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing C Rad's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

C Rad Stock Price History
DateC Rad Price
8/21/202634.90 SEK
8/20/202635.00 SEK
8/19/202635.60 SEK
8/17/202636.00 SEK
8/14/202636.00 SEK
8/13/202636.00 SEK
8/12/202635.40 SEK
8/11/202636.20 SEK
8/10/202636.20 SEK
8/7/202635.60 SEK
8/6/202635.60 SEK
8/5/202635.40 SEK
8/4/202635.50 SEK
7/31/202636.70 SEK
7/30/202636.70 SEK
7/29/202636.80 SEK
7/28/202637.30 SEK
7/27/202636.80 SEK
7/24/202637.10 SEK
7/23/202636.80 SEK
7/22/202637.50 SEK
7/21/202637.50 SEK
7/20/202637.50 SEK
7/17/202638.20 SEK
7/15/202637.40 SEK
7/14/202637.00 SEK
7/13/202636.00 SEK
7/10/202635.70 SEK
7/9/202636.20 SEK
7/8/202634.70 SEK
7/7/202636.00 SEK
7/6/202636.60 SEK
7/3/202636.00 SEK
7/2/202636.00 SEK
7/1/202636.90 SEK
6/30/202636.30 SEK
6/29/202636.40 SEK
6/26/202637.20 SEK
6/25/202638.20 SEK
6/24/202638.80 SEK
6/23/202637.50 SEK
6/22/202637.60 SEK
6/18/202636.90 SEK
6/17/202637.00 SEK
6/16/202636.90 SEK
6/15/202636.90 SEK
6/12/202636.00 SEK
6/11/202635.20 SEK
6/10/202635.30 SEK
6/9/202634.40 SEK
6/8/202635.00 SEK
6/5/202634.70 SEK
6/4/202634.40 SEK
6/3/202634.00 SEK
6/2/202634.10 SEK
6/1/202633.80 SEK
5/29/202634.30 SEK
5/28/202634.40 SEK
5/27/202634.10 SEK
5/26/202634.20 SEK
5/25/202635.00 SEK
5/22/202634.30 SEK
5/21/202635.70 SEK
5/20/202635.70 SEK
5/19/202635.40 SEK
5/18/202635.20 SEK
5/15/202634.00 SEK
5/13/202633.90 SEK
5/12/202634.40 SEK
5/11/202634.40 SEK
5/8/202633.70 SEK
5/7/202632.90 SEK
5/6/202631.50 SEK
5/5/202625.60 SEK
5/4/202625.80 SEK
4/30/202624.90 SEK
4/29/202625.10 SEK
4/28/202625.80 SEK
4/27/202627.20 SEK
4/24/202627.70 SEK
4/23/202627.80 SEK
4/22/202627.80 SEK
4/21/202627.50 SEK
4/20/202627.90 SEK
4/17/202627.50 SEK
4/16/202626.80 SEK
4/15/202626.90 SEK
4/14/202627.00 SEK
4/13/202626.80 SEK
4/10/202627.10 SEK
4/9/202626.90 SEK
4/8/202626.10 SEK
4/7/202625.80 SEK
4/2/202626.50 SEK
3/27/202625.50 SEK
3/26/202625.55 SEK
3/25/202626.50 SEK
3/24/202625.90 SEK
3/23/202625.80 SEK
3/20/202625.50 SEK
3/19/202625.45 SEK
3/17/202625.40 SEK
3/16/202625.30 SEK
3/13/202625.43 SEK
3/12/202625.60 SEK
3/11/202625.97 SEK
3/10/202625.93 SEK
3/9/202625.57 SEK
3/6/202625.75 SEK
3/5/202626.50 SEK
2/26/202627.75 SEK
2/25/202627.50 SEK
2/24/202627.65 SEK
2/23/202627.85 SEK
2/20/202627.90 SEK
2/19/202627.70 SEK
2/18/202628.56 SEK
2/17/202628.26 SEK
2/16/202628.10 SEK
2/13/202627.75 SEK
2/12/202627.64 SEK
2/11/202632.26 SEK
2/10/202631.65 SEK
2/9/202632.20 SEK
2/6/202631.60 SEK
2/5/202631.50 SEK
2/4/202631.02 SEK
2/3/202631.48 SEK
2/2/202631.80 SEK
1/30/202631.81 SEK
1/29/202631.90 SEK
1/28/202632.00 SEK
1/27/202632.95 SEK
1/26/202631.88 SEK
1/23/202631.65 SEK
1/22/202631.95 SEK
1/21/202631.55 SEK
1/20/202631.86 SEK
1/19/202631.88 SEK
1/16/202632.00 SEK
1/15/202632.09 SEK
1/14/202632.12 SEK
1/13/202632.30 SEK
1/12/202632.40 SEK
1/9/202631.80 SEK
1/8/202631.80 SEK
1/7/202631.85 SEK
1/5/202632.05 SEK
1/2/202631.42 SEK
12/30/202531.53 SEK
12/29/202531.27 SEK
12/23/202531.60 SEK
12/22/202531.05 SEK
12/19/202531.49 SEK
12/18/202531.40 SEK
12/17/202531.05 SEK
12/16/202531.24 SEK
12/15/202531.95 SEK
12/12/202531.98 SEK
12/11/202531.90 SEK
12/10/202532.18 SEK
12/9/202532.10 SEK
12/8/202532.53 SEK
12/5/202531.95 SEK
12/4/202532.00 SEK
12/3/202531.90 SEK
12/2/202532.30 SEK
12/1/202531.23 SEK
11/28/202532.79 SEK
11/27/202532.10 SEK
11/26/202532.47 SEK
11/25/202532.79 SEK
11/24/202534.10 SEK
11/21/202534.55 SEK
11/20/202534.53 SEK
11/19/202534.30 SEK
11/18/202534.70 SEK
11/17/202534.70 SEK
11/14/202533.98 SEK
11/13/202533.90 SEK
11/12/202532.06 SEK
11/11/202532.25 SEK
11/10/202532.30 SEK
11/7/202532.34 SEK
11/6/202533.03 SEK
11/5/202533.00 SEK
11/4/202533.16 SEK
11/3/202533.80 SEK
10/31/202533.20 SEK
10/30/202533.75 SEK
10/29/202534.13 SEK
10/28/202533.60 SEK
10/27/202533.90 SEK
10/24/202533.40 SEK
10/23/202533.70 SEK
10/22/202532.85 SEK
10/21/202533.45 SEK
10/20/202533.16 SEK
10/17/202533.00 SEK
10/16/202533.05 SEK
10/15/202532.88 SEK
10/14/202533.23 SEK
10/13/202533.52 SEK
10/10/202533.96 SEK
10/9/202533.15 SEK
10/8/202532.70 SEK
10/7/202532.95 SEK
10/6/202532.65 SEK
10/3/202532.23 SEK
10/2/202532.83 SEK
10/1/202532.35 SEK
9/29/202530.80 SEK
9/26/202530.00 SEK
9/25/202530.40 SEK
9/24/202530.05 SEK
9/23/202530.15 SEK
9/22/202530.10 SEK
9/19/202530.00 SEK
9/18/202530.15 SEK
9/17/202530.25 SEK
9/16/202529.79 SEK
9/15/202530.70 SEK
9/12/202531.95 SEK
9/11/202531.55 SEK
9/10/202531.72 SEK
9/9/202531.68 SEK
9/8/202531.70 SEK
9/5/202531.85 SEK
9/4/202532.20 SEK
9/3/202531.77 SEK
9/2/202532.31 SEK
9/1/202532.45 SEK
8/29/202532.80 SEK
8/28/202532.80 SEK
8/27/202533.10 SEK
8/26/202532.75 SEK
Access this data via the Eulerpool API
Get Free API Key

C Rad Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
424.62 M SEK
50.04 M SEK
35.53 M SEK
Jan 1, 2024
469.00 M SEK
70.55 M SEK
56.45 M SEK
Jan 1, 2025
441.90 M SEK
45.10 M SEK
10.50 M SEK
Jan 1, 2026 (e)
513.08 M SEK
104.03 M SEK
85.87 M SEK
Jan 1, 2027 (e)
573.68 M SEK
129.28 M SEK
107.08 M SEK
Jan 1, 2028 (e)
629.23 M SEK
0.00 SEK
0.00 SEK
Jan 1, 2029 (e)
693.93 M SEK
0.00 SEK
0.00 SEK
Jan 1, 2030 (e)
947.65 M SEK
0.00 SEK
0.00 SEK

C Rad Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 6:57 AM
 
REVENUEB SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
0.080.130.190.210.220.260.300.420.470.440.510.570.630.690.951.04
24.2462.2042.867.897.8018.1015.3340.8610.61-5.9716.3311.709.7710.1736.6510.03
19.5134.5935.2636.5941.6344.8342.8645.7546.9151.9351.9351.9351.9351.9351.9351.93
16.0046.0067.0075.0092.00117.00129.00194.00220.00229.00266.39297.54326.62359.86491.75541.08
-30.00-9.001.003.0020.0036.0021.0050.0070.0045.00104.00129.00––––
-36.59-6.770.531.469.0513.796.9811.7914.9310.2020.2722.51––––
-31.00-10.0021.00-13.0014.0025.007.0035.0056.0010.0085.00107.00––––
47.62-67.74-310.00-161.90-207.6978.57-72.00400.0060.00-82.14750.0025.88––––
25.7029.5931.1630.9433.2633.9333.7633.7733.7733.8733.8733.8733.8733.8733.8733.87
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales C Rad generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue C Rad retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare C Rad's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares C Rad has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against C Rad's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

C Rad stock margins

The C Rad margin analysis displays the gross margin, EBIT margin, as well as the profit margin of C Rad. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for C Rad.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
45.09 %
14.00 %
9.61 %
Jan 1, 2022
42.99 %
7.22 %
2.48 %
Jan 1, 2023
45.86 %
11.79 %
8.37 %
Jan 1, 2024
47.00 %
15.04 %
12.04 %
Jan 1, 2025
51.91 %
10.21 %
2.38 %
Jan 1, 2026 (e)
51.91 %
20.28 %
16.74 %
Jan 1, 2027 (e)
51.91 %
22.54 %
18.66 %
Jan 1, 2028 (e)
51.91 %
0.00 %
0.00 %

C Rad Stock Revenue, EBIT, Earnings per Share

The C Rad earnings per share therefore indicates how much revenue C Rad has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
7.70 SEK
1.08 SEK
0.74 SEK
Jan 1, 2022
8.92 SEK
0.64 SEK
0.22 SEK
Jan 1, 2023
12.57 SEK
1.48 SEK
1.05 SEK
Jan 1, 2024
13.89 SEK
2.09 SEK
1.67 SEK
Jan 1, 2025
13.05 SEK
1.33 SEK
0.31 SEK
Jan 1, 2026 (e)
15.15 SEK
3.07 SEK
2.54 SEK
Jan 1, 2027 (e)
16.94 SEK
3.82 SEK
3.16 SEK
Jan 1, 2028 (e)
18.58 SEK
0.00 SEK
0.00 SEK

C Rad business model & stock analysis

The company C Rad AB is a Swedish company based in Uppsala, founded in 1989. The company specializes in the development and production of products for medical imaging, particularly for radiology. Since its founding, the company has become a global provider of innovative solutions for radiology and nuclear medicine. The main goal of C Rad AB is to improve patient care and workflow in radiology by offering solutions that increase treatment efficiency and quality. C Rad's products are tailored to the needs of radiologists, technicians, and patients, aiming to make operation simple and intuitive. The company offers a wide range of products divided into various categories. One of the main categories is computed tomography (CT), for which C Rad has developed a range of accessories. These accessories aim to improve the image quality of CT scans and reduce the dose of ionizing radiation for patients and medical personnel. An example of such an accessory is a special software for analyzing lung images, which works in real time and enables radiologists to make quick and accurate diagnoses. Another important category for C Rad is magnetic resonance imaging (MRI). Here, the company offers a range of products that adapt to the needs of radiologists and patients. One such solution is magnetic muscle stimulation. This technology uses strong magnetic fields to stimulate patients' muscles, thereby positioning the body for better imaging. This type of solution is particularly useful for patients with limited mobility or individuals who have difficulty remaining still due to pain or discomfort. C Rad also develops products for radiation therapy. Here, the focus is on solutions that help control and reduce radiation dose for patients and medical personnel. Examples include dosimeters that measure radiation dose and allow technicians to accurately determine the radiation dose for each patient. In addition to accessories for medical imaging, C Rad also offers a wide range of software solutions. One such solution is Radimetrics software. This software uses machine learning technologies and provides real-time guidance to doctors and technicians on how to optimize workflow and reduce radiation dose for patients. Another example of C Rad's software solutions is dosimetry software. This solution allows technicians to monitor and control radiation dose and image quality in real time. Such software is particularly useful for monitoring radiation dose in radiation therapy and medical imaging. In conclusion, C Rad AB is a company characterized by innovation and quality. Through the continuous development of new solutions, they aim to improve the lives of patients and medical personnel and increase the efficiency and quality of radiology.

C Rad SWOT Analysis

Strengths

C Rad AB has several strengths that contribute to its success in the market. These include:

  • Strong brand reputation and recognition in the industry.
  • Highly skilled and experienced workforce.
  • Innovative and technologically advanced product portfolio.
  • Strong financial position and consistent profitability.

Weaknesses

Despite its strengths, C Rad AB also faces certain weaknesses that need to be addressed:

  • Dependency on a limited number of key customers.
  • Relatively limited market presence compared to competitors.
  • Difficulty in keeping up with rapidly evolving industry trends.
  • Challenges in maintaining competitive pricing.

Opportunities

C Rad AB should explore the following opportunities to further grow its business:

  • Expanding into new geographic markets with high growth potential.
  • Diversifying its product offerings to cater to emerging industry needs.
  • Forming strategic partnerships or acquisitions to enhance market reach.
  • Capitalizing on advancements in healthcare technology.

Threats

Alongside opportunities, C Rad AB must be aware of the potential threats it faces:

  • Intense competition from established industry players.
  • Changes in regulatory framework affecting product development and marketing.
  • Economic downturns impacting customer spending and demand.
  • Rapid technological advancements making existing products obsolete.

C Rad Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

C Rad historical P/E ratio, EBIT multiple, and P/S ratio

C Rad annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

C Rad shares outstanding

The number of shares of C Rad was 33.87 M in 2025. This indicates how many shares C Rad is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
33.93 M Stocks
Jan 1, 2022
33.76 M Stocks
Jan 1, 2023
33.77 M Stocks
Jan 1, 2024
33.77 M Stocks
Jan 1, 2025
33.87 M Stocks
Jan 1, 2026 (e)
33.87 M Stocks
Jan 1, 2027 (e)
33.87 M Stocks
Jan 1, 2028 (e)
33.87 M Stocks

C Rad Dividend History

1 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.10SEKYTD—1×
May 8, 20260.10SEK—1/1

C Rad dividend payout ratio

In 2025, C Rad had a payout ratio of 0.00%. The payout ratio indicates the percentage of the company's profits that C Rad distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
0.00 %
Jan 1, 2022
0.00 %
Jan 1, 2023
0.00 %
Jan 1, 2024
0.00 %
Jan 1, 2025
0.00 %
Jan 1, 2026 (e)
3.94 %
Jan 1, 2027 (e)
3.16 %
Jan 1, 2028 (e)
3.55 %

Current C Rad forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
80.00 % (4)
Hold
20.00 % (1)
Sell
0.00 % (0)
12M Price Target
44.88
Last Price
35.30
Currency
SEK
12M Return Potential
27.14 %
LTM Return
0 %

C Rad Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
1/24/20240.61SEK-127.26 MSEK-2023 Q4
1/26/20230.40SEK-96.42 MSEK-2022 Q4
10/28/20220.20SEK-76.63 MSEK-2022 Q3
7/21/20220.04SEK-60.90 MSEK-2022 Q2
5/6/20220.18SEK-67.50 MSEK-2022 Q1
1/27/20220.39SEK-82.72 MSEK-2021 Q4
10/28/20210.18SEK-65.47 MSEK-2021 Q3
7/29/20210.13SEK-60.90 MSEK-2021 Q2

EESG©

Eulerpool ESG Scorecard© for the C Rad stock

50/100
54
Environment
59
Social
37
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees32.258
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

C Rad shareholder structure

% Name
11.58799%
Svea Ekonomi AB
Svea Ekonomi AB
8.57665%
Cervantes Capital AB
Cervantes Capital AB
7.07168%
Linc AB
Linc AB
4.52277%
Avanza Bank Holding AB
Avanza Bank Holding AB
4.22804%
Nyberg (Lars)
Nyberg (Lars)
4.21591%
Nordnet Pensionsforsakring AB
Nordnet Pensionsforsakring AB

C Rad Executives and Management Board

15 members · avg. age 53 · 47 % women

CL

Ms. Cecilia De Leeuw (57)

Chief Executive Officer, President

3.67 M SEK

Management

LF

Ms. Linda Frolen (48)

Chief Financial Officer

–
IA

Mr. Ivan Astralaga (57)

President, C- RAD Americas

–
XW

Mr. Xiaodong Wang (46)

President, C- RAD China

–
HA

Mr. Hakan Axelsson (57)

Chief Operating Officer

–
VT

Mr. Vincent Tallier (46)

Vice President of Sales - EMEA

–
MP

Ms. Melinda Perjons

Vice President Global Marketing

–

Board of Directors

KW

Ms. Kristina Willgard (60)

Independent Chairman of the Board

495,000.00 SEK
JR

Ms. Jenny Rosberg (59)

Independent Director

275,000.00 SEK
SE

Ms. Susanne Ekblom (59)

Independent Director

245,000.00 SEK
PS

Mr. Peter Simonsbacka (65)

Independent Director

210,000.00 SEK
DS

Mr. David Sjoestroem (51)

Independent Director

200,000.00 SEK
MT

Mr. Mats Thoren (54)

Independent Director

100,000.00 SEK

Frequently asked questions about C Rad

The business model of C Rad AB is focused on providing innovative and advanced medical imaging solutions. C Rad AB is a company that specializes in developing and selling products for the radiation therapy market. They offer a range of solutions including advanced imaging tools and software designed to enhance the accuracy and efficiency of radiation therapy treatments. With a strong commitment to research and development, C Rad AB aims to provide healthcare professionals with cutting-edge technology that improves patient outcomes.

C Rad AB is primarily active in the medical technology industry.

The main competitors of C Rad AB in the market include Elekta AB, Varian Medical Systems Inc., and Accuray Incorporated.

C Rad AB is a Swedish medical technology company that specializes in innovative solutions for cancer treatment. Founded in 2004, C Rad AB has a rich history of developing advanced products for radiation therapy. With a strong focus on improving patient care, the company offers cutting-edge solutions like the C-RAD Catalyst system, which enhances accuracy and efficiency in radiotherapy. The company's commitment to research and development has made C Rad AB a trusted name in the field of oncology. With a vision to revolutionize cancer treatment, C Rad AB continues to make significant contributions to the medical industry through its state-of-the-art technologies and solutions.

C Rad AB has achieved several significant milestones since its inception. The company successfully developed innovative medical solutions, focusing on advanced imaging systems for radiation therapy. C Rad AB has gained notable recognition for its cutting-edge technologies and has received various awards for its exceptional contributions to the field. Additionally, the company has achieved significant collaborations with leading medical institutions and established a global presence by expanding its operations into multiple countries. C Rad AB continues to push boundaries, providing state-of-the-art solutions that enhance precision and safety in radiation therapy treatments.

C Rad AB is primarily present in Sweden.

C Rad AB represents values such as innovation, quality, and sustainability. As a company, C Rad AB is committed to delivering cutting-edge technology and solutions in the field of advanced radiation therapy. With a focus on developing and commercializing innovative products, C Rad AB aims to improve cancer treatment outcomes and enhance patient care. The company's corporate philosophy revolves around continuous research and development, collaboration with healthcare professionals, and a customer-centric approach. C Rad AB strives to make a positive impact on society by providing state-of-the-art solutions that contribute to the advancement of cancer care.

Analysts currently set an average price target of 44.88 SEK for the C Rad stock (median: 44.88 SEK), implying +27.1 % versus the latest price. The consensus is based on 5 analyst ratings.

C Rad Analyst Price Targets 2026

5 analysts currently rate the C Rad stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect C Rad to generate revenue of 513.08 M SEK and earnings per share of 2.54 SEK.

C Rad Analyst Price Targets 2026

Converted at the current exchange rate, the C Rad share trades at 3.16 EUR (34.90 SEK).

The C Rad share (CRAD B.ST) is listed on 4 stock exchanges, including: Frankfurt (24C.F), London (0R44.L).

The company C Rad AB is a leading provider of digital radiology and medical technology solutions. The company offers a wide range of products and services tailored to the needs of patients, doctors, and hospitals. One of the core divisions of C Rad AB is the development and manufacture of digital radiology systems, including Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and digital X-ray systems. These systems are capable of creating precise images of tissues and organs while enabling minimally invasive treatments. C Rad AB aims to improve patient care by focusing on the development of systems that enable precise and fast diagnoses. Another important business area is the development of medical software solutions. C Rad AB has developed a range of tools for digitally capturing, archiving, and analyzing radiological images. These analysis tools allow radiologists to make fast diagnoses and plan effective treatments. The software solutions also include a platform for data exchange and collaboration, making it easier for doctors and clinics to share patient images and data. C Rad AB also operates a number of diagnostic centers that offer a comprehensive range of health services. These centers provide rapid tests, radiology services, laboratory diagnostics, and other medical services. The centers are equipped with state-of-the-art technology and provide fast and accurate diagnoses for patients. Finally, C Rad AB also offers a variety of training and support services for patients and medical professionals. The company operates its own training academy, offering training for radiologists and medical personnel. Additionally, the company provides technical support and maintenance services for its products. Overall, the business model of C Rad AB is focused on offering innovative solutions for radiology and digital medicine. The company has a strong research and development department that is constantly working on new technologies and solutions. By combining top-quality products, services, and training, C Rad AB has strengthened its position as a leading provider of medical technology solutions.

The expected revenue of C Rad is 513.08 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of C Rad is 85.87 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of C Rad is currently 13.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the C Rad stock.

The price-to-sales ratio (P/S) of C Rad is currently 2.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the C Rad stock.

The Eulerpool Quality Score for C Rad is 6/10.

The ISIN of C Rad is SE0002016352. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of C Rad is A0X93X. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of C Rad is CRAD B.ST. The ticker symbol is used to trade C Rad shares on the stock exchange.

C Rad paid dividends every year for the past 6 years.

For the upcoming 12 months, dividends amounting to 0.10 SEK are expected. This corresponds to a dividend yield of 0.29 %.

C Rad is assigned to the 'Health' sector.

To receive the latest dividend of C Rad from amounting to 0.1 SEK, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of C Rad are distributed in SEK.

All fundamentals and in-depth analysis of C Rad

Our stock analysis for C Rad stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of C Rad. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

C Rad Stock
C Rad Revenue→
C Rad Stock
C Rad Net Income→
C Rad Stock
C Rad P/E→
C Rad Stock
C Rad P/S→
C Rad Stock
C Rad EBIT→
C Rad Stock
C Rad Dividend→
C Rad Stock
C Rad Directors Dealings→
C Rad Stock
C Rad Stocks→
C Rad Stock
C Rad Market capitalization→
C Rad Stock
C Rad Debt→
C Rad Stock
C Rad Liabilities→
C Rad Stock
C Rad Equity→
C Rad Stock
C Rad AAQS→
C Rad Stock
C Rad Employees→
C Rad Stock
C Rad ROE→
C Rad Stock
C Rad ROA→
C Rad Stock
C Rad ROCE→
C Rad Stock
C Rad News→
C Rad Stock
C Rad Analyst Price Targets→

Health Stocks

C-Mer Medical HoldingsButterfly NetworkC.Q. Pharmaceutical Holding CoBusiness Alignment PCLC&R ResearchBurzynski Research InstituteC21 InvestmentsBurning Rock BiotechC4 TherapeuticsBundamedik Tbk PTCabaletta BioBumrungrad Hospital PCLAll Stocks A–Z →